Table 2.
Univariate and multivariate logistic regression analysis of baseline variables associated with the achievement of the study primary endpoint in the ACHIEVE trial
| Variable | Incidence of primary endpoint | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| No (total = 12) | Yes (total = 78) | OR (95% CIs) | p | OR (95% CIs) | p | |
| Start of clarithromycin within the first 5 days for symptoms onset, n (%) | 4 (33.3) | 44 (56.4) | 3.49 (0.85–14.34) | 0.082 | 6.62 (1.19–32.63) | 0.030 |
| CCI, mean (SD) | 4.00 (2.95) | 2.14 (2.25) | 0.76 (0.60–0.96) | 0.019 | * | |
| Admission APACHE II score, mean (SD) | 8.00 (3.13) | 5.12 (3.79) | 0.84 (0.72–0.97) | 0.021 | * | |
| Admission SOFA score, mean (SD) | 2.16 (1.11) | 1.10 (1.13) | 0.51 (0.31–0.84) | 0.008 | 0.39 (0.22–0.68) | 0.001 |
| Admission PSI, mean (SD) | 80.7 (20.7) | 57.0 (26.9) | 0.97 (0.95–0.99) | 0.008 | * | |
| Lymphocytes/mm3, mean (SD) | 1126.9 (432.3) | 1366.5 (536.9) | 1.00 | 0.148 | ||
| CRP, mg/l, mean (SD) | 110.1 (180.2) | 63.7 (61.4) | 0.99 (0.99–1.00) | 0.094 | * | |
APACHE Acute Physiology and Chronic Health Evaluation, CCI Charlson’s Comorbidity Index, CI confidence interval, CRP C-reactive protein, n number, OR odds ratio, PSI pneumonia severity index, SOFA sequential organ failure assessment
*Variable did not enter the equation after three steps of the multivariate model